<DOC>
	<DOCNO>NCT01282658</DOCNO>
	<brief_summary>Irinotecan ( CPT-11 ) widely use first-line chemotherapy mCRC . There 4 key enzyme CPT-11 metabolizing , CYP3A4 , UDP-glucuronosyltransferase , carboxylesterase ( CES ) , ATP-binding cassette ( ABC ) transporter . Genetic variation enzyme may cause heterogeneity safety efficacy CPT-11 . The aim study figure correlation genetic polymorphism drug response .</brief_summary>
	<brief_title>Pharmacogenomics Study CPT-11 First-line Chemotherapy mCRC</brief_title>
	<detailed_description>collect blood sample , determine genetic contribution safety efficacy CPT-11 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>1 . Histologically confirm colorectal cancer 2 . ≥ 18 year old 3 . Measurable disease , define RECIST criterion 4 . Unresectable metastatic disease OR First recurrence/metastasis adjuvant therapy suitable operation 5 . FOLFIRI±cetuximab/bevacizumab firstline therapy 6 . Without expect course radiotherapy firstline chemotherapy 7 . No previous CPT11 chemotherapy 8 . ECOG performance status ( PS ) 02 9 . Not pregnant nursing Negative pregnancy test 10 . Voluntarily sign informed consent 11 . Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) 12 . AST ALT ≤ 2.5 time ULN ( ≤ 5 time ULN f liver metastasis present ) 13 . Creatinine clearance &gt; 50 mL/min OR serum creatinine ≤ 1.5 time ULN 1 . Brain metastasis obvious symptom 2 . Severe bone marrow failure correct 3 . Chronic diarrhea history 4 . Bowel obstruction without control 5 . Mental illness without control 6 . Clinically significant ( i.e. , active ) cardiovascular disease , include follow : Cerebrovascular accidents/ Myocardial infarction/ Unstable angina/ New York Heart Association class IIIV congestive heart failure/ Serious cardiac arrhythmia require medication/ Uncontrolled hypertension 7 . Other coexist malignancy malignancy diagnose within past 5 year , except basal cell squamous cell carcinoma , carcinoma situ cervix 8 . Pelvic radiotherapy past 1 year 9 . Known allergy component study medication 10 . Serious , nonhealing wound ulcer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>CPT-11 , pharmacogenomics , colorectal cancer</keyword>
</DOC>